Sotrovimab
Sotrovimab Uses, Dosage, Side Effects, Food Interaction and all others data.
Sotrovimab (VIR-7831), also known as GSK4182136, is a monoclonal antibody with the ability to neutralize the SARS-CoV-2 virus. On May 26, 2021 the FDA granted GlaxoSmithKline and Vir Biotechnology emergency use authorization for sotrovimab in the treatment of mild-to-moderate COVID-19. This authorization was based on interim results from a clinical trial, demonstrating that treatment with sotrovimab resulted in an 85% reduction in the risk of death or hospitalization in high-risk adults with COVID-19 in the outpatient setting. A fact sheet for healthcare providers is currently available.
Sotrovimab is a monoclonal antibody that treats mild-to-moderate COVID-19 by binding to and neutralizing the spike protein of SARS-CoV-2.
| Trade Name | Sotrovimab |
| Availability | Prescription only |
| Generic | Sotrovimab |
| Sotrovimab Other Names | Sotrovimab |
| Related Drugs | Paxlovid, molnupiravir, remdesivir, Actemra, Pfizer-BioNTech COVID-19 Vaccine, tocilizumab |
| Type | |
| Weight | 149000.0 Da |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Sotrovimab is a monoclonal antibody for the treatment of mild-to-moderate COVID-19 in patients at increased risk for death or hospitalization.
Sotrovimab is authorized for use under FDA's Emergency Use Authorization (EUA) for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARSCoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.
Sotrovimab is also used to associated treatment for these conditions: Mild-to-moderate COVID-19
How Sotrovimab works
Sotrovimab is a recombinant human IgG1κ monoclonal antibody that acts by binding to a conserved epitope located on the spike protein receptor-binding domain of SARS-CoV-2, the virus causing COVID-19. The epitope is highly conserved, discouraging the development of viral resistance to the antibody. This prevents the spike protein mediated binding of SARS-CoV-2 and entry into human cells. Sotrovimab does not compete with human ACE2 receptor binding and inhibits an undefined step that occurs after viral attachment and before the fusion of the viral and cell membranes. The Fc component of sotrovimab includes M428L and N434S amino acid substitutions (LS modification) that result in a longer half-life.
Toxicity
There are currently no data available regarding an overdose with sotrovimab, and LD50 information is not available. If an overdose occurs, provide symptomatic and supportive treatment as required.
Food Interaction
No interactions found.Sotrovimab Drug Interaction
Moderate: covid-19 ad26 vaccine, recombinant, covid-19 chadox1 vaccine, recombinant, covid-19 mrna-1273 vaccine, covid-19 nvx-cov2373 vaccine, recombinant, covid-19 rs-nanoparticle vaccine, recombinant, tozinameran 5y-11y vaccine, tozinameran 6m-4y vaccine, tozinameran-tris-sucrose vaccine, tozinameran vaccine, 6m-5y vaccine, 6y-11y vaccine, booster only vaccine, booster only vaccine, recombinant
Volume of Distribution
Sotrovimab is an Fc-enhanced human immunoglobulin G (IgG), and therefore has the potential for placental transfer.
Elimination Route
A non-compartmental analysis determined that the mean Cmax after a 1 hour IV infusion of sotrovimab was 137 µg/mL and the mean Day 29 concentration was 34 µg/mL.
Half Life
This antibody has undergone modifications for a potentially extended half-life and enhanced lung bioavailability. The half-life of sotrovimab is longer than Fc-unmodified IgG due to the LS modification, however, specific values are not available in the literature.
Innovators Monograph
You find simplified version here Sotrovimab
